Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines

Lobba, Aline Ramos Maia; Forni, Maria Fernanda; Carreira, Ana Cláudia Oliveira; Sogayar, Mari Cleide

doi:10.1002/cyto.a.22220

Cited by 37 publications

(30 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although CD90's exact function is currently unknown, it has been implicated to have a significant role in cellular adhesion and migration, regulating cell-cell and cell-matrix interactions [31]. Besides its expression on certain normal cell types, CD90 has been described as a CSC marker in various malignancies, such as hepatocellular carcinoma, esophageal cancer, glioma, and lung and breast cancers [16][17][18][19][20]. In this study, we demonstrated for the first time that CD90 also appears to be a potential CSC marker for INS, because CD90…”

Section: Discussionmentioning

confidence: 99%

“…CD90 demonstrated to be such a marker, as CD90-positive INS cells demonstrated a more tumorigenic behavior in vivo compared with CD90-negative INS cells. CD90 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that has been correlated with the tumorigenicity of hepatocellular carcinoma, esophageal cancer, glioma, and lung and breast cancers [16][17][18][19][20]. On top of that, through binding to avb3 integrin, CD90 has been implicated to facilitate metastasizing behavior in melanomas, by establishing an intimate connection between melanoma cells and activated endothelium [21].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas

Buishand

Arkesteijn

Feenstra

et al. 2016

Stem Cells and Development

View full text Add to dashboard Cite

The long-term prognosis after surgical resection of malignant insulinoma (INS) is poor. Novel adjuvant therapies, specifically targeting cancer stem cells (CSCs), are warranted. Therefore, the goal of this study was to characterize and target putative INS CSCs. Using fluorescence-activated cell sorting, human INS cell line CM and pancreatic carcinoid cell line BON1 were screened for the presence of stem cell-associated markers. CD90, CD166, and GD2 were identified as potential CSC markers. Only CD90 + INS cells had an increased tumor-initiating potential in athymic nude mice. Anti-CD90 monoclonal antibodies decreased the viability and metastatic potential of injected cells in a zebrafish embryo INS xenograft model. Primary INS stained positive for CD90 by immunohistochemistry, however also intratumoral fibroblasts and vascular endothelium showed positive staining. The results of this study suggest that anti-CD90 monoclonals form a potential novel adjuvant therapeutic modality by targeting either INS cells directly, or by targeting the INS microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas

Buishand

Arkesteijn

Feenstra

et al. 2016

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…In breast cancer, CD90 was expressed in highly metastatic breast cancer cell lines MDA-MB-231 [109] and Hs578-T and had an inverse correlation with CD14, which is usually expressed in non-metastatic cell lines [14]. In breast tumor samples (24 samples), CD90 was co-expressed highly with CD44 in cancer cells and high CD90 was also seen in CD44 negative intra-tumor stromal cells [110].…”

Section: Cd90 Regulates Metastasismentioning

confidence: 98%

“…CD90 is a GPI-anchored cell surface protein which is involved in cell-cell and cell-matrix interaction and has been implicated in several cancers. In many cancers, CD90 expression identifies the cancer stem cells [7][8][9][10][11][12][13] and overexpression in the tumor microenvironment promotes cancer proliferation and dissemination [3,14,15]. In others, CD90 expression causes inhibition of tumor invasion and anchorage independent growth [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Multiple roles of CD90 in cancer

et al. 2016

View full text Add to dashboard Cite

THY1 (CD90) is a 25-37-kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein. It is usually expressed on thymocytes, mesenchymal stem cells, hematopoietic stem cells, natural killer cells, neurons, endothelial cells, renal glomerular mesangial cells, follicular dendritic cells, fibroblasts, and myofibroblasts. It has been found to regulate cell adhesion, migration, apoptosis, axon growth, cell-cell and cell-matrix interactions, T-cell activation, and fibrosis. Several reports have shown that CD90 has an important role in cancer in regulating cancer cell proliferation, metastasis, and angiogenesis. There are also evidences that CD90 is an important prognostic marker in many cancers. Consequently, therapies that target CD90 have great promise in treating many cancers. However, several studies also indicate a contradictory role for CD90, where it acts as a tumor suppressor. In this review, we summarize the expression, function of CD90 in different cancers and its possible use as a biomarker or a therapeutic target in cancer. The challenges and future prospects for the use of CD90 for clinical applications are also discussed in this review.

show abstract

“…cells demonstrate self-renewing properties as well as higher tumor-promoting capacity and cell proliferation ability [32,33]. In different breast cancer cell lines, CD90 was found to be highly expressed in the malignant cell lines [34]. Moreover, in many different tumors CD90 was proposed to be a cancer stem cell marker and a possible target for the diagnosis and therapy of the malignancies [35][36][37].…”

Section: Discussionmentioning

confidence: 98%

Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9

et al. 2015

View full text Add to dashboard Cite

Cancer and stem cells exhibit similar features, including self-renewal, differentiation and immortality. The expression of stem-cell-related genes in cancer cells is demonstrated to be potentially correlated with cancer cell behaviour, affecting both drug response and tumor recurrence. There is an emerging body of evidence that subpopulations of tumors carry a distinct molecular sign and are selectively resistant to chemotherapy. Therefore, it is important to find novel therapeutic agents that could suppress the stem-like features of cancer cells while inhibiting their proliferation. Myrtucommulone-A (MC-A) is an active compound of a nonprenylated acylphloroglucinol isolated from the leaves of myrtle. Here we have investigated the potential of MC-A in inhibiting the expression of self-renewal regulatory factors and cancer stem cell markers in a bladder cancer cell line HTB-9. We used RT-PCR, immunocytochemistry, flow cytometry and western blotting to examine the expression of pluripotency- and multipotency-associated markers with or without treatment with MC-A. Treatment with MC-A not only decreased cancer cell viability and proliferation but also resulted in a decrease in the expression of pluripotency- and multipotency-associated markers such as NANOG, OCT-4, SOX-2, SSEA-4, TRA-1-60, CD90, CD73 and CD44. MC-A treatment was also observed to decrease the sphere-forming ability of HTB-9 cells. In summary, this study provides valuable information on the presence of stem-cell marker expression in HTB-9 cells and our results imply that MC-A could be utilized to target cancer cells with stem-like characteristics.

show abstract

Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines

Cited by 37 publications

References 42 publications

Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas

Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas

Multiple roles of CD90 in cancer

Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9

Contact Info

Product

Resources

About